title: Impact of extended ginsenoside Rb1 on early chronic kidney disease: a randomized, placebo-controlled study.
abstract: Ginsenoside Rb1 (GS-Rb1) is a well-known antioxidant derived from traditionally used herbal medicine ginseng. It has been suggested that reactive oxygen species (ROS) is involved in chronic kidney disease (CKD) in which GS-Rb1 may play a protective role. The aim of this study was to evaluate prospectively the effects of GS-Rb1 in patients with early chronic kidney disease. 197 patients who have been diagnosed with early CKD (stage 2 or 3) were recruited and randomly assigned to receive GS-Rb1 (500 mg daily oral administration, n = 103) or placebo (n = 94) for consecutive 6 months. Analytical procedures performed at baseline, the end of the treatments, and 6 months after the treatments included renal function evaluation (creatinine and urea clearance), oxidative stress measurement, inflammation assessment, and lipid profile. Of 177 patients completing the study, the GS-Rb1 group (n = 91) showed a positive response in significantly alleviating renal function impairments compared to the placebo group (n = 86). In addition, GS-Rb1 treatment was effective in reducing the extent of oxidative stress and inflammation in CKD patients, whereas continued deterioration was observed in the placebo group. Thus, extended treatment of patients using GS-Rb1 may present an antioxidant-based approach to slow the progression of CKD at the early stages.
authors.affiliation: Department of Nephrology, Wuxi No. 2 People's Hospital Affiliated to Nanjing Medical University, No. 68, Zhongshan Rd, Wuxi, 214002, China.
authors.forename: Xuefang
authors.initials: X
authors.lastname: Xu
authors.affiliation: Department of Nephrology, Wuxi No. 2 People's Hospital Affiliated to Nanjing Medical University, No. 68, Zhongshan Rd, Wuxi, 214002, China.
authors.forename: Qiandi
authors.initials: Q
authors.lastname: Lu
authors.affiliation: Department of Nephrology, Wuxi No. 2 People's Hospital Affiliated to Nanjing Medical University, No. 68, Zhongshan Rd, Wuxi, 214002, China.
authors.forename: Jingyue
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Nephrology, Wuxi No. 2 People's Hospital Affiliated to Nanjing Medical University, No. 68, Zhongshan Rd, Wuxi, 214002, China.
authors.forename: Yixiang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Nephrology, Wuxi No. 2 People's Hospital Affiliated to Nanjing Medical University, No. 68, Zhongshan Rd, Wuxi, 214002, China. Sunjz9925@163.com.
authors.forename: Jinzhu
authors.initials: J
authors.lastname: Sun
mesh_terms: D000368:Aged; D004334:Drug Administration Schedule; D042241:Early Diagnosis; D005260:Female; D036145:Ginsenosides / Q000008:administration & dosage*; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000097:blood; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D005894:Panax; D011446:Prospective Studies; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D036145:Ginsenosides; D018836:Inflammation Mediators; C442759:ginsenoside Rb1
keywords: Chronic kidney disease; Ginsenoside; Inflammation; Oxidative stress; Renal function